MECANISMOS DE SEÑALIZACIÓN EN ENFERMEDADES CARDIOVASCULARES Y OTRAS PATOLOGÍAS: DE LA INVESTIGACIÓN BÁSICA A LA CLÍNICA
Hospital Universitario Virgen de la Victoria
Málaga, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de la Victoria (6)
2021
-
Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with pre-existing primary immune thrombocytopenia (ITP) in Spain
British Journal of Haematology, Vol. 194, Núm. 3, pp. 537-541
2020
-
Reducing residual thrombotic risk in patients with peripheral artery disease: Impact of the COMPASS trial
Drugs in Context, Vol. 9
-
Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition
Expert Review of Clinical Pharmacology, Vol. 13, Núm. 7, pp. 695-706
2015
-
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score
Leukemia Research, Vol. 39, Núm. 1, pp. 52-57
-
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43
-
Use of eltrombopag after romiplostim in primary immune thrombocytopenia
British Journal of Haematology, Vol. 169, Núm. 1, pp. 111-116